{"id":69832,"date":"2026-07-13T15:55:29","date_gmt":"2026-07-13T07:55:29","guid":{"rendered":"https:\/\/flcube.com\/?p=69832"},"modified":"2026-07-13T15:55:30","modified_gmt":"2026-07-13T07:55:30","slug":"hansoh-pharmas-b7-h3-adc-risvutatug-rezetecan-meets-primary-endpoint-in-phase-iii-sclc-trial-showing-significant-survival-benefit-over-topotecan","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69832","title":{"rendered":"Hansoh Pharma&#8217;s B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Hansoh Pharmaceutical Group Company Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3692:HKG\">HKG: 3692<\/a>) announced that <strong>Risvutatug Rezetecan (HS-20093)<\/strong>, its proprietary <strong>B7-H3-targeted antibody-drug conjugate (ADC)<\/strong>, has <strong>met the primary endpoint of overall survival (OS)<\/strong> in the pivotal <strong>Phase III ARTEMIS-008 trial<\/strong> for patients with <strong>small cell lung cancer (SCLC)<\/strong> whose disease progressed or relapsed following platinum-based therapy.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-results\" class=\"wp-block-heading\">Clinical Trial Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result (HS-20093 vs. Topotecan)<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Statistically significant and clinically meaningful improvement in Overall Survival (OS)<\/td><\/tr><tr><td><strong>Secondary Endpoints<\/strong><\/td><td>Consistent benefits observed across all secondary endpoints including Progression-Free Survival (PFS)<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Consistent with previous studies; no new safety signals identified<\/td><\/tr><tr><td><strong>Analysis Type<\/strong><\/td><td>Pre-specified interim analysis<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>SCLC patients with disease progression\/relapse after platinum-based therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The positive results from the ARTEMIS-008 trial represent a potential breakthrough for SCLC treatment, a disease area with limited therapeutic options and poor long-term outcomes.<\/p>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Risvutatug Rezetecan (HS-20093)<\/li>\n\n\n\n<li><strong>Class:<\/strong> B7-H3-targeted antibody-drug conjugate (ADC)<\/li>\n\n\n\n<li><strong>Structure:<\/strong> Fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor (TOPOi) payload<\/li>\n\n\n\n<li><strong>Target:<\/strong> B7-H3 (CD276), an immune checkpoint protein overexpressed in multiple solid tumors<\/li>\n\n\n\n<li><strong>Developer:<\/strong> Independently developed by Hansoh Pharmaceutical<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">B7-H3 represents an emerging target in oncology with expression across various tumor types while showing limited expression in normal tissues, potentially offering a favorable therapeutic window.<\/p>\n\n\n\n<h2 id=\"h-development-pipeline-status\" class=\"wp-block-heading\">Development Pipeline Status<\/h2>\n\n\n\n<h3 id=\"h-china-hansoh-pharma\" class=\"wp-block-heading\">China (Hansoh Pharma)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase III:<\/strong> Osteosarcoma, Small Cell Lung Cancer, Non-Small Cell Lung Cancer<\/li>\n\n\n\n<li><strong>Proof-of-Concept Studies:<\/strong> Head and neck cancer, prostate cancer, esophageal squamous cell carcinoma, colorectal cancer, and other solid tumors<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-global-glaxosmithkline\" class=\"wp-block-heading\">Global (GlaxoSmithKline)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Licensing Agreement:<\/strong> Exclusive global license granted in December 2023 (excluding Chinese Mainland, Hong Kong, Macau, and Taiwan)<\/li>\n\n\n\n<li><strong>Current Status:<\/strong> GSK advancing Phase I and Phase III clinical trials overseas<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-partnership-with-gsk\" class=\"wp-block-heading\">Strategic Partnership with GSK<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Deal Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partner<\/strong><\/td><td>GlaxoSmithKline (GSK)<\/td><\/tr><tr><td><strong>Agreement Date<\/strong><\/td><td>December 2023<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Global (excluding Greater China region)<\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td>Exclusive license for development, manufacturing, and commercialization<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Leverages GSK&#8217;s global oncology expertise and commercial infrastructure<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The partnership validates the potential of HS-20093 as a best-in-class B7-H3 ADC and provides Hansoh with significant non-dilutive funding and global development capabilities.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-commercial-potential\" class=\"wp-block-heading\">Market Impact &amp; Commercial Potential<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SCLC Market Opportunity:<\/strong> Addresses significant unmet need in second-line SCLC with limited effective treatments<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Potential to become standard of care in relapsed\/refractory SCLC if approved<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Substantial milestone payments and royalties from GSK partnership plus direct sales in China<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Success validates Hansoh&#8217;s ADC platform and B7-H3 targeting approach across multiple indications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Small cell lung cancer accounts for approximately 10-15% of all lung cancer cases globally, with most patients experiencing disease progression within months of initial treatment. The demonstrated survival benefit represents a meaningful advance for this patient population.<\/p>\n\n\n\n<h2 id=\"h-regulatory-pathway-amp-next-steps\" class=\"wp-block-heading\">Regulatory Pathway &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China NMPA:<\/strong> Submission of New Drug Application (NDA) based on ARTEMIS-008 results<\/li>\n\n\n\n<li><strong>Global Regulatory Strategy:<\/strong> GSK to lead regulatory submissions in international markets<\/li>\n\n\n\n<li><strong>Additional Indications:<\/strong> Continued development in osteosarcoma, NSCLC, and other solid tumors<\/li>\n\n\n\n<li><strong>Commercial Preparation:<\/strong> Manufacturing scale-up and market access planning<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory approvals, and commercial expectations. Actual results may differ due to risks including final trial data, regulatory decisions, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that Risvutatug Rezetecan (HS-20093), its proprietary B7-H3-targeted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,16,17,363,1182],"class_list":["post-69832","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-clinical-trial-results","tag-hansoh-pharmaceutical","tag-hkg-3692"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hansoh Pharma&#039;s B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that Risvutatug Rezetecan (HS-20093), its proprietary B7-H3-targeted antibody-drug conjugate (ADC), has met the primary endpoint of overall survival (OS) in the pivotal Phase III ARTEMIS-008 trial for patients with small cell lung cancer (SCLC) whose disease progressed or relapsed following platinum-based therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69832\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hansoh Pharma&#039;s B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan\" \/>\n<meta property=\"og:description\" content=\"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that Risvutatug Rezetecan (HS-20093), its proprietary B7-H3-targeted antibody-drug conjugate (ADC), has met the primary endpoint of overall survival (OS) in the pivotal Phase III ARTEMIS-008 trial for patients with small cell lung cancer (SCLC) whose disease progressed or relapsed following platinum-based therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69832\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-13T07:55:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-13T07:55:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69832#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69832\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hansoh Pharma&#8217;s B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan\",\"datePublished\":\"2026-07-13T07:55:29+00:00\",\"dateModified\":\"2026-07-13T07:55:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69832\"},\"wordCount\":551,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Clinical trial results\",\"Hansoh Pharmaceutical\",\"HKG: 3692\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69832#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69832\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69832\",\"name\":\"Hansoh Pharma's B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-13T07:55:29+00:00\",\"dateModified\":\"2026-07-13T07:55:30+00:00\",\"description\":\"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that Risvutatug Rezetecan (HS-20093), its proprietary B7-H3-targeted antibody-drug conjugate (ADC), has met the primary endpoint of overall survival (OS) in the pivotal Phase III ARTEMIS-008 trial for patients with small cell lung cancer (SCLC) whose disease progressed or relapsed following platinum-based therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69832#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69832\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69832#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hansoh Pharma&#8217;s B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hansoh Pharma's B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan - Insight, China&#039;s Pharmaceutical Industry","description":"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that Risvutatug Rezetecan (HS-20093), its proprietary B7-H3-targeted antibody-drug conjugate (ADC), has met the primary endpoint of overall survival (OS) in the pivotal Phase III ARTEMIS-008 trial for patients with small cell lung cancer (SCLC) whose disease progressed or relapsed following platinum-based therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69832","og_locale":"en_US","og_type":"article","og_title":"Hansoh Pharma's B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan","og_description":"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that Risvutatug Rezetecan (HS-20093), its proprietary B7-H3-targeted antibody-drug conjugate (ADC), has met the primary endpoint of overall survival (OS) in the pivotal Phase III ARTEMIS-008 trial for patients with small cell lung cancer (SCLC) whose disease progressed or relapsed following platinum-based therapy.","og_url":"https:\/\/flcube.com\/?p=69832","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-13T07:55:29+00:00","article_modified_time":"2026-07-13T07:55:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69832#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69832"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hansoh Pharma&#8217;s B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan","datePublished":"2026-07-13T07:55:29+00:00","dateModified":"2026-07-13T07:55:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69832"},"wordCount":551,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Cancer","Clinical trial results","Hansoh Pharmaceutical","HKG: 3692"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69832#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69832","url":"https:\/\/flcube.com\/?p=69832","name":"Hansoh Pharma's B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-13T07:55:29+00:00","dateModified":"2026-07-13T07:55:30+00:00","description":"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that Risvutatug Rezetecan (HS-20093), its proprietary B7-H3-targeted antibody-drug conjugate (ADC), has met the primary endpoint of overall survival (OS) in the pivotal Phase III ARTEMIS-008 trial for patients with small cell lung cancer (SCLC) whose disease progressed or relapsed following platinum-based therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69832#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69832"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69832#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hansoh Pharma&#8217;s B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69832"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69832\/revisions"}],"predecessor-version":[{"id":69833,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69832\/revisions\/69833"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}